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Abstract
Purpose This study was designed to retrospectively
analyze outcomes of axillofemoral bypass (AxFB) opera-
tions performed in patients with severe comorbidities.
Methods All patients (n = 45) who received an AxFB
between 1990 and 2005 for aortoiliac occlusive disease
(AIOD, n = 35) or infectious aortic disease (IAD, n = 10)
were included. Information on patency of the bypass and
mortality was retrieved from patient records. A Kaplan–
Meier survival analysis was performed to illustrate survival
rates, limb salvage, and primary and secondary patency.
Results Included patients had several comorbidities and a
high operative risk. In this group, a 30-day mortality rate of
20% was found: 17% for the AIOD group, and 30% for the
IAD group. During 5-year follow-up 20 patients died, of
which 15 during the ﬁrst year after operation. Survival rates
were at 64 and 41% at 1 and 5 years and limb salvage rates
were 84% for both these years. Primary patency rates at 1
and 5 years were 72 and 58%, respectively, and secondary
patency rates were 86% at both time points.
Conclusions High mortality rates were found in AIOD or
IAD patients who received an AxFB. However, for high-
risk patients with an already reduced life expectancy, the
AxFB remains an alternative with acceptable patency rates.
Introduction
The axillo(bi)femoral bypass (AxFB) operation is an
alternative to direct arterial reconstruction, such as aor-
tobifemoral grafting. This procedure is performed in
patients with aortic graft sepsis or a mycotic aneurysm and
in patients with a totally occluded abdominal aorta with a
high operative risk. The advantage of the AxFB operation
is that it is a less invasive operation compared with a total
reconstruction of the aorta and that no surgical replacement
of the infected aortobifemoral graft is required in the
‘‘hostile’’ abdomen.
Previous retrospective studies in groups varying in size
from 34 to 108 patients who underwent surgery for aor-
toiliac occlusive disease (AIOD) or infectious aortic dis-
ease (IAD; infected aortic graft or mycotic aneurysm)
reported 30-day mortality rates after AxFB surgery
between 4 and 13%. Primary patency rates at 5 years
varied widely from 57 to 74% [1–6].
Compared with the AxFB, aortic bifurcation grafts for
aortoiliac occlusive disease or for replacement of the
infected aortic graft give higher survival rates, lower 30-day
mortality, and appear to have better patency rates from
previous studies [6–11]. Thirty-day mortality varies from
3.9 to 8% in these patients and the survival rate after 5 years
is approximately 63–89%. Furthermore, the primary
patency after 5 years varies from 70 to 89%. These out-
comes are generally better than the reported outcomes for
the AxFB in both AIOD and IAD patients, but in these
patients with several comorbidities and a high operative risk
aortic surgery is not preferable. The survival rates after
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risky operation, such as the AxFB, might be a good alter-
native. Although several previous studies are performed in
AxFB grafting, the current role of the AxFB for the man-
agement of AIOD and IAD in high-risk patients is not clear.
For this reason, this study was designed to investigate
indications, risk factors, comorbidities, and outcomes of
AxFB surgery for AIOD or IAD. Limb salvage, primary
and secondary patency rates, and mortality of the AxFB
operation were analyzed.
Methods
The medical records of patients who received an AxFB
between 1990 and 2005 in the BLINDED (Amphia hos-
pital, Breda, the Netherlands) were retrospectively ana-
lyzed. Information about cardiovascular risk factors,
previous operations, and existing comorbidities was
obtained from the patient records. Risk factors included
smoking, diabetes, hyperlipidemia, hypertension, coronary
artery disease, and cerebrovascular disease. Six staff vas-
cular surgeons performed the AxFB operation under gen-
eral anesthesia based on two different indications.
Routinely, two vascular surgeons operated as a team to
reduce the operation time.
The ﬁrst indication for AxFB operation was aortoiliac
occlusive disease (AIOD) in patients who had a high oper-
ativeriskasaresultofimpairedfunctionofoneormorevital
organs. The operative risk was classiﬁed according the ASA
classiﬁcation by an anesthesiologist [12]. Patients with
recent myocardial infarction, congestive heart failure, sig-
niﬁcantanginalsymptoms,chronicobstructivelungdisease,
or chronic renal insufﬁciency were candidates for axillofe-
moral grafting (ASA class III). The second indication was
infectious aortic disease (IAD) in patients with an infected
abdominal aorta or aortic graft sepsis.
All patients received duplex scanning and/or CT or
catheter angiography preoperatively to evaluate the extent
of lower extremity disease. Graft placement was done with
a PTFE or Dacron bypass of 6- or 8-mm diameter.
Information on 30-day mortality rates, survival time,
and graft patency was obtained from patient records. When
possible, a follow-up of 5 years was performed in the
outpatient clinic. The general practitioner from each patient
who terminated outpatient clinic follow-up was contacted.
The graft patency was evaluated by clinical examination,
ankle-arm indices, and/or duplex scanning. Kaplan–Meier
survival analysis was used to plot survival, limb salvage,
and primary and secondary patency rates. Differences in
survival rate and primary patency for graft type (Dacron or
PTFE), graft size, and the site of anastomosis were calcu-
lated with the log-rank test.
Results
A total of 46 patients received an AxFB. One patient was
excluded from analysis because the patient records were
lost. Therefore, 45 patients remained for analysis: 29 men
and 16 women. Eighteen patients received an axillounife-
moral bypass, and 27 patients were treated with an axil-
lobifemoral bypass. The median age of the total patient
group was 70 (range 45–85) years. All patients had ASA
class III or higher. In comparison, only 64% of patients
who received an aortobifemoral bypass in our hospital had
this ASA classiﬁcation. Table 1 shows patient character-
istics with cardiovascular risk factors, existing comorbidi-
ties, and previous operations. There were no signiﬁcant
differences in risk factors between AIOD and IAD patients.
A PTFE bypass was placed in 25 patients (of which 21
with AIOD), a Dacron bypass in 17 patients (13 with
AIOD), and in 3 patients the type of bypass was unknown.
To prevent graft occlusion, before 2000, all patients were
treated after surgery with anticoagulation to reach an
INR[2.5. After publication of the BOA trail, our hospital
guidelines were adjusted and all patients were treated with
antiplatelet therapy [13].
The 30-day mortality rate was 20% (9/45 patients).
During 5 years of follow-up, 20 patients died and 15 of
these patients died during the ﬁrst year after operation.
Figure 1 shows the Kaplan–Meier survival curves after
5-year follow-up, and Table 2 shows patients at risk and
survival rates per interval. Follow-up varied from 1 to 60
(median 16) months. The graft occluded in 14 patients
(31%) during follow-up. Amputation was needed in six
patients. The limb salvage rate at 1 year was 84% and at
5 years also was 84% (see Table 3 for limb salvage rates).
Primary patency rates at 1, 3, and 5 years were 72, 58, and
58%, respectively. The Kaplan–Meier curves of the pri-
mary patency are shown in Fig. 2, and the cumulative
patency rates per interval are shown in Table 4. The sec-
ondary patency at 1 year was 86% and remained equal in
the following years (Fig. 3 and Table 5). Survival and
patency were not different between patients with a Dacron
or PTFE bypass (P[0.05). Furthermore, the graft size did
not inﬂuence survival (P[0.05). However, primary
patency of the 8-mm grafts was better than that of the
6-mm grafts (P\0.05). Primary patency after 1 year of
follow-up in patients with 8-mm grafts was 80% compared
with 69% for the 6-mm grafts.
In 22 patients the distal anastomosis of the bypass was
made to the common femoral artery, in 9 patients to the
superﬁcial femoral, and in 9 patients to the profunda
femoral artery. In ﬁve patients, the site of anastomosis was
not stated in the operation ﬁles. The site of anastomosis and
the preoperative patency of the femoral artery did not lead
to different outcomes of primary patency (P[0.05).
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two different indications.
Aortoiliac occlusive disease (AIOD)
This group consisted of 35 high-risk patients; 10 patients
had an occluded abdominal aorta, 6 had a total occlusion of
the iliac artery, 4 had a thrombus in the original aor-
tobifemoral graft, and 15 had an infrarenal calciﬁed aortic
wall. The mean age of these patients was 70.2 years.
Smoking was the most prevalent risk factor with 77% (see
Table 1 for more patient characteristics).
The following indications for surgery in the AIOD
group were described: 2 patients with claudication, 22
suffered from rest pain, 10 had established tissue loss, and
for 1 patient the indication was not described. Median
length of hospital stay was 18 (range, 9–65) days. Six
patients (17%) died within 1 month of operation. One
patient died from a disseminated intravascular coagula-
tion, which led to pulmonary emboli and gastrointestinal
bleeding, three patients developed sepsis, and two patients
died from a cerebrovascular accident. Figure 1 shows the
Kaplan–Meier survival curves with a 5-year follow-up (see
Table 2 for interval rates).
In total, the graft occluded in 12 patients (34%) during
follow-up. Two patients received a second AxF bypass
because of an occlusion of the former AxF bypass, both due
toathrombosisofthesubclavianartery.Onepatientreceived
a femorofemoral crossover bypass. In six cases thrombec-
tomy or urokinase treatment was performed to treat the
occluded graft. Amputation took place in three patients as
primary intervention after occlusion of the graft. An ampu-
tationafteraprimaryintervention,e.g.,lowerlegamputation
or thrombectomy, was performed in two patients in this
group. Limb salvage was 83% after 1 and 5 years. Five
patientsunderwentasecondaryinterventionforreocclusion.
Table 1 Patient characteristics
Data in parentheses are
percentage of total number in
group
COPD chronic obstructive
pulmonary disease
a Malignancies that occurred
during the period of AxFB
operation: mamma carcinoma,
colon carcinoma, larynx
carcinoma and bronchus
carcinoma
b This includes: aortoiliac or
femoral bypass, femoropopliteal
bypass, femorofemoral bypass
and iliofemoral bypass
Total (N = 45) Aortoiliac occlusive
disease (n = 35)
Infectious aortic
disease (n = 10)
Patient characteristics
Age in years (range) 70 (45–85) 70 (48–85) 64 (45–80)
Male 29 (64%) 21 (60%) 8 (80%)
Cardiovascular risk factors
Smoking 32 (71%) 24 (77%) 8 (80%)
Hypertension 23 (51%) 19 (58%) 4 (40%)
Diabetes 12 (27%) 10 (29%) 2 (20%)
Coronary heart disease 16 (36%) 13 (37%) 3 (30%)
Hyperlipidemia 19 (42%) 15 (43%) 4 (40%)
Cerebrovascular disease 14 (31%) 10 (29%) 4 (40%)
Comorbidities
Malignancy
a 4 (9%) 4 (11%) 0
COPD 12 (27%) 11 (31%) 1 (10%)
Chronic renal insufﬁciency 3 (7%) 2 (6%) 1 (10%)
Previous operations
Amputation of upper or lower leg 6 (13%) 4 (11%) 2 (20%)
Bypass operation for arterial occlusive disease
b 14 (31%) 10 (29%) 4 (40%)
Fig. 1 In the left ﬁgure
survival until 5 years is shown
for the total group and in the
right ﬁgure for the infectious
aortic disease group (—) and the
aortoiliac occlusive disease
group (–). The censored points
(d and ?) are the patients who
were lost during follow-up
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at 1, 3, and 5 years were 69, 51, and 51% respectively. The
Kaplan–Meier curves of the primary patency are shown in
Fig. 2 (see Table 4 for interval patency rates). The sec-
ondary patency at 1 year was 86% and remained equal in
the following years (Fig. 3).
Infectious aortic disease (IAD)
The 10 patients with IAD had a median age of 64 years.
Median length of hospital stay was 42 (range, 2–99) days.
Most patients had multiple risk factors (Table 1). Three
patients (30%) died within 1 month of operation: one
patient died due to multiple organ failure, one patient had a
cardiac arrest, and one appeared to die from rupture of the
aortic stump. No autopsy was performed in this last patient.
The Kaplan–Meier survival curves for this patient group
are shown in Fig. 1.
During the ﬁrst year, two bypasses obstructed, which led
to thrombectomy, but in the following years none of the
other bypasses obstructed. The primary patency rate at 1, 3,
and 5 years was therefore 80% (Fig. 2). Only one of the
two bypasses that was obstructed occluded again within a
few days, resulting in a secondary patency of 90% during
5 years of follow-up. This bypass reocclusion resulted in
an amputation. Limb salvage at 1 year was 90%. None of
the patients had an infection of the AxFB graft after their
operation.
Discussion
In the literature various outcomes in patency and mortality
rates of the axillofemoral bypass have been reported. In
this study we evaluated the outcomes of high-risk patients
who received an AxFB in our hospital for aortoiliac
occlusive disease (AIOD) or infectious aortic disease
(IAD). For the whole population, our results showed a high
30-day mortality rate of 20% and acceptable patency rates:
Table 3 Limb salvage rates of the axillofemoral bypass for both
AIOD and IAD patients All patients (both AIOD and IAD)
Interval
(year)
No.
patients
at risk
No.
amputations
No. patients
withdrawn
a
Cumulative
limb salvage
(%)
SE
(%)
0–1 45 6 17 84 6.0
1–2 22 0 3 84 6.0
2–3 19 0 5 84 6.0
3–4 14 0 3 84 6.0
4–5 11 0 0 84 6.0
a Patients were withdrawn because of death or were lost to follow-up.
Rates for the AIOD group and IAD group are not given separately,
but numbers are mentioned in the text
Table 2 Survival rates axillofemoral bypass for AIOD and IAD
Interval
(year)
No. patients
at risk
No.
deaths
No. patients
withdrawn
a
Cumulative
survival (%)
SE
(%)
All patients (both AIOD and IAD)
0–1 45 15 7 64 7.5
1–2 23 1 2 61 7.7
2–3 20 2 4 54 8.4
3–4 14 2 1 46 8.8
4–5 11 0 3 46 8.8
AIOD
0–1 35 11 7 65 8.6
1–2 17 1 2 61 9.0
2–3 14 2 3 50 10.2
3–4 9 0 1 50 10.2
4–5 8 0 2 50 10.2
IAD
0–1 10 4 0 60 15.5
1–2 6 0 0 60 15.5
2–3 6 0 1 48 16.4
3–4 5 2 0 36 16.1
4–5 3 0 1 36 16.1
a Patients were withdrawn because they were lost to follow-up
Fig. 2 In the left ﬁgure
primary patency until 5 years is
shown for the total group and in
the right ﬁgure for the infectious
aortic disease group (—) and the
aortoiliac occlusive disease
group (–). The censored points
(d and ?) are the patients who
were lost during follow-up
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12372% for primary patency and 86% for secondary patency at
1 year follow-up.
Considering only the AIOD group, we found a mortality
rate of 17%. This is much higher than in a similar study by
Martin and Katz where in 60 patients the 30-day mortality
rate was only 4.9%. The mean age of this group was
74 years and there were comparable percentages of
comorbidities, e.g., diabetes and smoking [5]. Schneider
et al. describe a 30-day mortality rate of 9% (3/34 patients)
in their AxFB group, but during hospitalization three other
patients died in this study, resulting in a hospital mortality
rate of 18% [14]. This was relatively high compared with
the aortobifemoral bypass group in this same study with a
mortality rate of 1% during hospitalization. It must be
considered, however, that the patients in the AxFB group
were older and had more major risk factors than the aor-
tobifemoral bypass patients in this study. Therefore, the
difference in mortality rates in AxFB studies might be due
to the differences in comorbidities and the patients’ phys-
ical condition preoperatively. Patients with more comor-
bidities have a lower life expectancy and have less chance
of survival after operation. The median age of AIOD
patients in our study was 71 and many had comorbidities,
indicating that these patients have a low life expectancy,
which may explain the high mortality rate after operation
in this population. The hospital stay was long in both
patient groups in our study, because almost half of the
patients had postoperative complications, such as wound
infections, urine tract infections complicated with sepsis,
pneumonia, and neurologic complaints.
Regarding graft patency, somewhat different outcomes
were found in previous studies. We found a primary
patency rate of 49% at 3 years for the AIOD patients,
which was 72% in the study by Martin and Katz and 63%
by Schneider et al. [5, 14]. In our study two patients (6%)
received a second AxFB graft because of occlusion of the
primary graft. Both of these secondary AxFB grafts
remained patent, but in nearly all patients with graft failure
who were treated with urokinase, thrombectomy, or
amputation in this study, the graft did not remain patent
Table 4 Primary patency axillofemoral bypass for AIOD and IAD
Interval
(year)
No.
grafts at
risk
No.
occluded
grafts
No. patients
withdrawn
a
Cumulative
patency (%)
SE
(%)
All patients (both AIOD and IAD)
0–1 45 11 16 72 7.6
1–2 18 1 2 68 8.1
2–3 15 2 2 58 9.5
3–4 11 0 3 58 9.5
4–5 8 0 0 58 9.5
AIOD
0–1 35 9 13 69 8.9
1–2 13 1 2 64 9.7
2–3 10 2 2 49 12
3–4 6 0 1 49 12
4–5 5 0 0 49 12
IAD
0–1 10 2 3 80 12.6
1–2 5 0 0 80 12.6
2–3 5 0 0 80 12.6
3–4 5 0 2 80 12.6
4–5 3 0 0 80 12.6
a Patients were withdrawn because of death or were lost to follow-up
Fig. 3 In the left ﬁgure
secondary patency until 5 years
is shown for the total group and
in the right ﬁgure for the
infectious aortic disease group
(—) and the aortoiliac occlusive
disease group (–). The censored
points (d and ?) are the
patients who were lost during
follow-up
Table 5 Secondary patency axillofemoral bypass for AIOD and IAD
Interval
(year)
No.
grafts at
risk
No.
occluded
grafts
No. patients
withdrawn
a
Cumulative
patency (%)
SE
(%)
All patients (both AIOD and IAD)
0–1 45 5 20 86 6.1
1–2 20 0 3 86 6.1
2–3 17 0 4 86 6.1
3–4 13 0 3 86 6.1
4–5 10 0 2 86 6.1
a Patients were withdrawn because of death or were lost to follow-up
Rates for the AIOD group and IAD group are not given separately, but
numbers are mentioned in the text
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Olson et al. examined the results of repeat AxFB grafting
as treatment for graft failure. They found that AxFB
replacement and/or anastomotic revision had a superior
patency to thrombectomy. At 18 months mean patency
after thrombectomy was 11%, whereas patency for graft
replacement was 54% [15]. These rates seem to be con-
sistent with our results. We, therefore, think that AxFB
replacement, especially after a proximal occlusion (e.g.,
stenosis of the subclavian artery), should be the ﬁrst pro-
cedure of choice.
Considering the results of AxFB grafting in the infec-
tious aortic disease group, we found different outcomes
than several earlier published studies in similar AxFB-
grafted patients. The infectious 30-day mortality rate in the
infectious aortic disease group in our study was high
(30%). Previously a postoperative mortality rate of 13%
was found in patients who received an AxFB after removal
of the infected aortic graft [2]. Comparable postoperative
mortality rates (11–15%) were found for treatment of aortic
graft infection with extra-anatomic bypass grafting [1, 16].
Another treatment option for aortic graft infection is
excision of the infected aortic graft and a simultaneous
placement of a new aortic graft. There are several types of
grafts available, such as a vein autograft or a prosthetic
graft. In studies where those graft replacements were
studied, the 30-day mortality varied from 8 to 20% and the
5-year primary patency from 66 to 91% [7, 17, 18].
Furthermore, Johnson et al. found that the use of dif-
ferent types of grafts for the AxFB operation results in
similar long-term patencies [19]. Although in this study we
did not ﬁnd a signiﬁcant difference in outcomes of patency
between both types of grafts, when comparing the graft
size, we found a signiﬁcantly better primary patency for the
largest size (8 mm vs. 6 mm). This difference might be due
to an increased wall sheer stress in the smaller diameter
graft, which could increase the probability to develop ste-
nosis [20]. Therefore, we now prefer to use the 8-mm graft
for AxFB operations.
A limitation of this study was the long time period
(1990–2005) in which patients were included and followed.
This raises the possibility of a change in practice patterns
and variability due to advances in perioperative care during
the study period. We were, however, not able to identify
those changes and thus to analyze their inﬂuence. Because
of the relatively poor outcomes of AxFB compared with
other operations, such as an aortobifemoral bypass, we
adjusted the management of operating high-risk patients in
our hospital. In recent years only high-risk patients with a
very short life expectancy (\5 years) are treated with an
AxFB. This is contrary to an increase in abdominal endo-
vascular therapy in our hospital; during the period from
1990 to 2000, 150 endovascular procedures were
performed yearly, and from 2000 more than 200 proce-
dures yearly. In our practice, endovascular therapy is now
the preferred option for treatment of occlusive arterial
disease. The AxFB is applied only in speciﬁc cases in
which endovascular therapy is not possible.
Another limitation of this study is that it was based on
retrospective research and clinical records, which are not
always complete. A prospective study with closer atten-
dance to follow-up might have gathered more information
on factors predictive of graft failure, including information
on the patency of the superﬁcial femoral arteries and the
pre- and postoperative ankle-arm indices.
Conclusions
The axillofemoral bypass operation has relatively high
postoperative mortality rates but acceptable patency out-
comes in our study. The high mortality rates are partially
explained by an already short life expectancy of patients. In
patients with a reasonable life expectancy alternative treat-
ment, such as aortofemoral bypass for aortoiliac occlusive
disease or autogenous graft for infectious aortic disease,
may be preferred. However, for high-risk patients with a
reduced life expectancy, axillofemoral bypass is still an
acceptable alternative for treatment of aortoiliac occlusive
disease or infectious aortic disease.
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